Cellebrite and Chainalysis Partner to Modernize Digital Investigations by Unlocking Cryptocurrency Data

·6 min read
Cellebrite DI Ltd
Cellebrite DI Ltd

Two market leaders come together to expand digital investigations

PETAH TIKVA, Israel and TYSONS CORNER, Va. and NEW YORK, July 05, 2022 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, and Chainalysis, the blockchain data platform, have launched a partnership to enable customers to easily identify and assess criminal activity involving cryptocurrency during digital investigations to expedite their resolution.

Cryptocurrency usage has increased significantly over the past several years. While the vast majority of its use is for legitimate purposes, it has also been exploited for illicit use in scamming, money laundering, ransomware, and more. As cryptocurrency artifacts are more frequently found in, and can be used as key pieces of, digital evidence, law enforcement and corporations need access to cryptocurrency-related knowledge and tools to investigate criminal activity and help solve cases.

Together, Cellebrite and Chainalysis are enabling customers to modernize investigations by leveraging the transparency of blockchains. The integrated solution will provide automated, efficient capabilities and knowledge to identify and assess cryptocurrency risks and correlate such information to additional elements of a related case. Cellebrite’s DI suite of solutions will reveal accurate, real-time cryptocurrency data and insights from Chainalysis’ data platform. As a result of this cooperation, examiners, investigators, analysts, and compliance officers will be able to seamlessly identify illicit cryptocurrency-related activity in a single place as part of their familiar digital investigation workflows.

Cellebrite and Chainalysis are also collaborating to empower customers to bridge the cryptocurrency knowledge gap. Together, they will educate customers' internal experts by offering cryptocurrency training and delivering cryptocurrency expert investigation services, as well as making Chainalysis’ Reactor, the investigation tool, available for advanced cryptocurrency tracing.

“Cryptocurrency, as any other financial instrument, has become a vehicle for funding crime and laundering money, and as its adoption increases, our customers must be equipped with cutting-edge solutions to identify this important category of digital evidence,” said Leeor Ben-Peretz, Chief Strategy Officer at Cellebrite. “Providing our customers with an integrated cryptocurrency investigation solution will expedite their investigations through automation and help them seamlessly uncover a wider range of digital evidence within Cellebrite’s suite of Digital Intelligence solutions. We are happy to join forces with Chainalysis to further enhance our customers’ tools and knowledge, modernize investigations, and accelerate justice.”

“We are thrilled to partner with Cellebrite, the Digital Intelligence market leader, to expand our public and private sector customer reach and provide them access to Chainalysis’ solutions, training, and expertise,” said Thomas Stanley, President and Chief Revenue Officer at Chainalysis. “Together, Cellebrite and Chainalysis are committed to helping combat blockchain-related crime, improving trust and transparency in blockchains, and making cryptocurrency safer for all.”

The initial integrated solution is expected to be available in Q3 2022. To find out more about the partnership offerings, please visit: https://cellebrite.com/en/cellebrite-crypto-solution-powered-by-chainalysis/

About Cellebrite

Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

About Chainalysis

Chainalysis is the blockchain data platform. We provide data, software, services, and research to government agencies, exchanges, financial institutions, and insurance and cybersecurity companies in over 70 countries. Our data powers investigation, compliance, and market intelligence software that has been used to solve some of the world's most high-profile criminal cases and grow consumer access to cryptocurrency safely. Backed by Accel, Addition, Benchmark, Coatue, GIC, Paradigm, Ribbit, and other leading firms in venture capital, Chainalysis builds trust in blockchains to promote more financial freedom with less risk. For more information, visit www.chainalysis.com.

Caution Regarding Forward Looking Statements 
This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the acceptance of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; political and reputational factors related to Cellebrite’s business or operations; risks relating to estimates of market opportunity and forecasts of market growth; Cellebrite’s ability to properly manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third-party suppliers for certain components, products, or services; challenges associated with large transactions and long sales cycle; risks that Cellebrite’s customers may fail to honor contractual or payment obligations; risks associated with a significant amount of Cellebrite’s business coming from government customers around the world; risks related to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions; the mishandling or perceived mishandling of sensitive or confidential information; the complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on form 20-F filed with the SEC on March 29, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Cellebrite Media   
Victor Cooper
Public Relations and Corporate Communications Director
+1 404.804.5910
Victor.cooper@cellebrite.com

Cellebrite Investors
Anat Earon-Heilborn
VP Investor Relations
+972 73 394 8440
investors@cellebrite.com

Chainalysis Media
Maddie Kennedy
Senior Director of Communications
media@chainalysis.com
Contact Chainaylsis